Health
Optimi Health Has Completed the Largest Legal Harvest of Natural Psilocybin in Canadian History.
A native Canadian firm, Optimi Health Corp. (OPTI:CNX), makes synthetic formulations for transformative human experiences as well as natural, scaleable, and affordable psychedelic and functional mushrooms. The organization is included on Health Canada’s list of ... [Read]
Health
Cardinal Health Reveals Governance Enhancements And Shareholder Value Creation Programs
Cardinal Health (NYSE:CAH) recently announced steps to position the Company for long-term success, expanding on previously disclosed expansion goals. Elliott Investment Management L.P. (“Elliott”) provided feedback on these efforts. Elliott has also signed a collaboration ... [Read]
Biotechnology
FDA Approves Bayer’s Nubeqa for Wider Use in Prostate Cancer Subtype.
In combination with docetaxel, the U.S. Food and Drug Administration (FDA) has approved Bayer’s Nubeqa for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC).Nubeqa (darolutamide) was previously approved for the treatment of non-metastatic castration-resistant prostate ... [Read]
Health
The Phase 1b study by Aligos Therapeutics to assess its Class II Capsid Assembly modulator, ALG-000184, started with a 12-week dosing cohort.
The clinical-stage biopharmaceutical company Aligos Therapeutics, Inc. (Nasdaq:ALGS), which focuses on creating novel treatments for unmet medical needs in viral and liver diseases, announced today that enrollment in a 12-week dosing cohort of HBeAg-positive chronic ... [Read]
Health
Emergent executes a letter of intent to acquire Evolutionary Biologics; former L’Oréal president Jim Morrison will become Emergent’s full-time chief executive officer.
Emergent Health Corp. (“Emergent”) (OTC PINK:EMGE) announces it has executed a Letter of Intent to acquire Evolutionary Biologics, Inc. Biologics, Inc. is a new type of biologics company with a specific mission: to provide the ... [Read]
Biotechnology
FDA provides a positive pre-IND response to Alzamend Neuro for AL001.
Alzamend Neuro, Inc. (Nasdaq:ALZN) is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”), and post-traumatic stress disorder (“PTSD”), announced today ... [Read]
Biotechnology
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA
Amryt (Nasdaq: AMYT), a multinational, commercial-stage biopharmaceutical company with a focus on acquiring, developing, and commercializing novel treatments for rare diseases, today announced its intention to submit a Formal Dispute Resolution Request (FDRR) for its ... [Read]
Biotechnology
Eton Pharmaceuticals Sells Hospital Supplies to Dr. Reddy’s for up to $50M
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today declared that it had agreed to sell its hospital goods to Dr. Reddy’s Laboratories SA, a ... [Read]
Biotechnology
Evaxion Biotech Broadens EVX-03 DNA Vaccine Project Into Non-Small Cell Lung Cancer.
Evaxion Biotech A/S (NASDAQ: EVAX) a clinical-stage biotechnology company focused on the creation of AI-driven immunotherapies, announced today that it has chosen EVX-03 as the product candidate within its DNA technology platform to target a ... [Read]
Biotechnology
Optimi Health Requests for Authorization to Manufacture MDMA, Other Synthetic Psychedelics
Optimi Health Corp, a native Canadian business that creates natural, scalable, and affordable mushroom formulations for transformational human experiences, has made a health request to Canada for an amendment to the Controlled Substances Dealer’s Licence. ... [Read]